A Promising DNA Methylation Signature for the Triage of High-Risk Human Papillomavirus DNA-Positive Women
Open Access
- 19 March 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (3) , e91905
Abstract
High-risk human papillomavirus (hrHPV)-DNA testing is frequently performed parallel to cytology for the detection of high-grade dysplasia and cervical cancer particularly in women above 30 years of age. Although highly sensitive, hrHPV testing cannot distinguish between HPV-positive women with or without clinically relevant lesions. However, in principle discrimination is possible on the basis of DNA methylation markers. In order to identify novel DNA regions which allow an effective triage of hrHPV-positive cases, hypermethylated DNA enriched from cervical cancers was compared with that from cervical scrapes of HPV16-positive cases with no evidence for disease by CpG island microarray hybridization. The most promising marker regions were validated by quantitative methylation-specific PCR (qMSP) using DNA from archived cervical tissues and cervical scrapes. The performance of these markers was then determined in an independent set of 217 hrHPV-positive cervical scrapes from outpatients with histopathological verification. A methylation signature comprising the 5′ regions of the genes DLX1, ITGA4, RXFP3, SOX17 and ZNF671 specific for CIN3 and cervical cancer (termed CIN3+) was identified and validated. A high detection rate of CIN3+ was obtained if at least 2 of the 5 markers were methylated. In the subsequent cross-sectional study all cervical carcinomas (n = 19) and 56% (13/23) of CIN3 were identified by this algorithm. Only 10% (11/105) of hrHPV-positive women without histological evidence of cervical disease were scored positive by the methylation assay. Of note is that the detection rate of CIN3 differed between age groups. Eight of nine CIN3 were detected among women ≥30 years of age but only five of fourteen among <30 year old group (p = 0.03). The specificity for CIN3+ in the older age group was 76.6% (95% CI 65.6–85.5%). Clinical validation studies are required to determine the usefulness of these novel markers for triage after primary hrHPV testing in a cervical cancer screening setting.Keywords
This publication has 36 references indexed in Scilit:
- Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomasCarcinogenesis, 2012
- Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican PopulationJNCI: Journal of the National Cancer Institute, 2012
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomasGynecologic Oncology, 2010
- Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancyVirology, 2009
- Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-scienceGynecologic Oncology, 2009
- Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing CountriesVaccine, 2008
- Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap testsCancer, 2008
- Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trialThe Lancet, 2007
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006